Plasma Adsorption to Prevent Pancreatic Cancer Spread During Surgery
Part of Cancer clinical trials.
This trial tests whether a special blood-filtering treatment (plasma adsorption to remove extracellular DNA) given during surgery can help prevent pancreatic cancer from spreading. It is for people with non-metastatic pancreatic cancer who are scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of non-metastatic pancreatic ductal adenocarcinoma (cancer that has not spread beyond the pancreas).
- You are in good physical condition (able to do daily activities without help).
- You are scheduled for surgery to remove the tumor, and you have either not had chemotherapy before or have completed neoadjuvant (pre-surgery) chemotherapy.
- You do not have any other known cancer.
- You do not have conditions that would make plasma adsorption unsafe, such as low blood pressure, bleeding problems, or severe heart or lung issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.